Abstract | OBJECTIVE: The aim of this study was to evaluate the efficacy of a therapeutic pathway for vestibular migraine (VM) and complex dizziness of undetermined etiology (CDUE) with caffeine cessation and pharmacotherapy. STUDY DESIGN: This study is a retrospective chart review. INTERVENTION(S): MAIN OUTCOME MEASURE: Self-reported dizziness is the main outcome measure. RESULTS: Vestibular migraine and CDUE were considered contributing factors to dizziness in 34 and 10, respectively, of 156 patients. Fourteen percent of patients reported improvement in symptoms upon caffeine cessation, whereas 46% of patients reported a reduction in dizziness after nortriptyline therapy (P = .007). Topiramate reduced symptoms in 25% of patients. In total, 75% of VM patients and 56% of patients with CDUE received sufficient benefit from this therapeutic pathway to not progress to other treatments. CONCLUSIONS:
|
Authors | Anthony A Mikulec, Farhoud Faraji, Laurence J Kinsella |
Journal | American journal of otolaryngology
(Am J Otolaryngol)
2012 Jan-Feb
Vol. 33
Issue 1
Pg. 121-7
ISSN: 1532-818X [Electronic] United States |
PMID | 21704423
(Publication Type: Journal Article)
|
Copyright | Copyright © 2012 Elsevier Inc. All rights reserved. |
Chemical References |
- Adrenergic Uptake Inhibitors
- Neuroprotective Agents
- Topiramate
- Fructose
- Caffeine
- Nortriptyline
|
Topics |
- Adrenergic Uptake Inhibitors
(therapeutic use)
- Adult
- Aged
- Aged, 80 and over
- Caffeine
(administration & dosage)
- Dizziness
(drug therapy)
- Female
- Fructose
(analogs & derivatives, therapeutic use)
- Humans
- Male
- Middle Aged
- Migraine Disorders
(drug therapy)
- Neuroprotective Agents
(therapeutic use)
- Nortriptyline
(therapeutic use)
- Retrospective Studies
- Topiramate
- Treatment Outcome
|